Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($1.05), $0.12 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $0 versus the consensus estimate of $18.58 million.

GUIDANCE:

2022 Financial Outlook

The Company is reaffirming its prior operational expense guidance. Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million. Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.

Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.